Uncovering the Tumor Antigen Landscape : What to Know about the Discovery Process

Näytä kaikki kuvailutiedot



Pysyväisosoite

http://hdl.handle.net/10138/318431

Lähdeviite

Feola , S , Chiaro , J , Martins , B & Cerullo , V 2020 , ' Uncovering the Tumor Antigen Landscape : What to Know about the Discovery Process ' , Cancers , vol. 12 , no. 6 , 1660 . https://doi.org/10.3390/cancers12061660

Julkaisun nimi: Uncovering the Tumor Antigen Landscape : What to Know about the Discovery Process
Tekijä: Feola, Sara; Chiaro, Jacopo; Martins, Beatriz; Cerullo, Vincenzo
Tekijän organisaatio: ImmunoViroTherapy Lab
Division of Pharmaceutical Biosciences
Drug Research Program
Helsinki Institute of Life Science HiLIFE
TRIMM - Translational Immunology Research Program
Digital Precision Cancer Medicine (iCAN)
Päiväys: 2020-06
Kieli: eng
Sivumäärä: 28
Kuuluu julkaisusarjaan: Cancers
ISSN: 2072-6694
DOI-tunniste: https://doi.org/10.3390/cancers12061660
URI: http://hdl.handle.net/10138/318431
Tiivistelmä: According to the latest available data, cancer is the second leading cause of death, highlighting the need for novel cancer therapeutic approaches. In this context, immunotherapy is emerging as a reliable first-line treatment for many cancers, particularly metastatic melanoma. Indeed, cancer immunotherapy has attracted great interest following the recent clinical approval of antibodies targeting immune checkpoint molecules, such as PD-1, PD-L1, and CTLA-4, that release the brakes of the immune system, thus reviving a field otherwise poorly explored. Cancer immunotherapy mainly relies on the generation and stimulation of cytotoxic CD8 T lymphocytes (CTLs) within the tumor microenvironment (TME), priming T cells and establishing efficient and durable anti-tumor immunity. Therefore, there is a clear need to define and identify immunogenic T cell epitopes to use in therapeutic cancer vaccines. Naturally presented antigens in the human leucocyte antigen-1 (HLA-I) complex on the tumor surface are the main protagonists in evocating a specific anti-tumor CD8+ T cell response. However, the methodologies for their identification have been a major bottleneck for their reliable characterization. Consequently, the field of antigen discovery has yet to improve. The current review is intended to define what are today known as tumor antigens, with a main focus on CTL antigenic peptides. We also review the techniques developed and employed to date for antigen discovery, exploring both the direct elution of HLA-I peptides and the in silico prediction of epitopes. Finally, the last part of the review analyses the future challenges and direction of the antigen discovery field.
Avainsanat: tumor antigens
immunopeptidome
cancer immunotherapy
epitope prediction
MHC CLASS-I
CYTOLYTIC T-LYMPHOCYTES
MASS-SPECTROMETRIC IDENTIFICATION
DISTINCT PROTEOLYTIC PROCESSES
TAP TRANSPORT EFFICIENCY
CELL EPITOPES
PREDICTING IMMUNOGENICITY
BINDING PEPTIDES
IMMUNE-RESPONSES
HIGH-THROUGHPUT
3111 Biomedicine
3122 Cancers
317 Pharmacy
Vertaisarvioitu: Kyllä
Tekijänoikeustiedot: cc_by
Pääsyrajoitteet: openAccess
Rinnakkaistallennettu versio: publishedVersion


Tiedostot

Latausmäärä yhteensä: Ladataan...

Tiedosto(t) Koko Formaatti Näytä
cancers_12_01660.pdf 1.165MB PDF Avaa tiedosto

Viite kuuluu kokoelmiin:

Näytä kaikki kuvailutiedot